



miamidade.gov

Management and Budget
Grants Coordination
Ryan White Program
111 NW 1st Street • 19th Floor
Miami, Florida 33128
T 305-375-4742 F 305-375-4454

December 10, 2012

SENT VIA ELECTRONIC MAIL

Dear Ryan White Part A and/or MAI-funded Outpatient Medical Care Service Providers:

For informational purposes, at the recommendation of the Miami-Dade County Medical Care Subcommittee to the Care and Treatment Committee, and presented for approval by the Miami-Dade HIV/AIDS Partnership on Monday, December 10, 2012; this letter serves as information for physicians to consider before starting patients (clients) on the new antiretroviral medication Stribild (elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil fumarate).

As you are aware, effective immediately, at its meeting on Monday, December 10, 2012, the Miami-Dade HIV/AIDS Partnership approved the addition of Stribild to the Ryan White Program Prescription Drug Formulary as a lifesaving medication. According to the Partnership, because of the cost associated with Stribild and possible renal affects, this medication should be used primarily for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in antiretroviral (ARV) naïve adult clients, and any switches from prior ARV therapy regimens should be dictated by medical necessity.

It is imperative that this information and/or recommendation be immediately shared with all physicians involved in direct provision of services under your organization's Part A and/or MAI-funded service agreements, who are considering starting patients (clients) on Stribild. See attached Interoffice Memorandum from the Florida Department of Health, dated October 1, 2012, and prescribing information from Gilead Sciences, revised August 2012, for more details.

If further clarification is needed related to this recommendation for physicians to consider before starting patients (clients) on Stribild, please contact Carla Valle-Schwenk, Ryan White Program Administrator, at (305) 375-4742. Thank you for your continued cooperation.

Sincerely,

Theresa Fiaño
OMB Coordinator

Attachments

c: Carla Valle-Schwenk, Program Administrator, OMB-GC/RW
Clarisol Nilsen, Fiscal Administrator, OMB-GC/RW
Andrae Corrigan, President, ACMS, Inc. (local office)
Dr. Robert A. Ladner, President, Behavioral Science Research Corporation
Beth Hayden, Senior Administrator, Behavioral Science Research Corporation

Believing Excellence Every Day